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Abstract
Background: Diethylnitrosamine is a well known carcinogen that induces cancers of various organs in mice and
rats. Using FVB/N mouse strain, here we show that diethylnitrosamine induces primarily lung adenocarcinomas with
modest tumor development in the liver, offering a new model to study chemical carcinogenesis in the lung.
Methods: Animals were exposed to a single high dose of diethylnitrosamine, and more than 70% of the mice
developed lung cancer. To obtain a new transplantable tumor line, pieces of primary tumors were inoculated and
maintained subcutaneously in the same mouse strain. We used immunohistochemistry to characterize the tumor
for main lung adenocarcinoma markers. We searched for mutations in KRAS exon 2 and EGFR exon 19, 21 with
Sanger sequencing. We also compared the normal lung tissue with the diethylnitrosamine induced primary
adenocarcinoma, and with the subcutaneously maintained adenocarcinoma using Western blot technique for main
cell cycle markers and to identify the main pathways.
Results: Primary and subcutaneous tumors express cytokeratin-7 and thyroid transcription factor-1, markers
characteristic to lung adenocarcinoma. In addition, no mutations were found in the hot spot regions of KRAS and
EGFR genes. We found high mTOR activation, but the level of p-Akt Ser473 and p-Akt Thr308 decreased in the
tumorous samples.
Conclusions: We established a new lung adenocarcinoma model using FVB/N mouse strain and
diethylnitrosamine. We believe that this new model system would be highly useful in lung cancer research.
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Background
Cancer is the second leading cause of death nowadays
[1, 2]. Lung cancer is the most frequent tumor all over
the world which claims the most life among other can-
cer types in Europe and in the United States [1, 2]. Ac-
cording to their phenotype and clinical behavior lung
cancers are divided to two major types: small cell lung
cancer (SCLC) and non-small cell lung cancer (NSCLC).
NSCLC is the more common type of lung carcinomas
[3]. In the US 85% of the lung cancers are NSCLC [3].
In the last decade adenocarcinomas became the domin-
ant representative within NSCLC [4]. These NSCLCs ex-
press proteins such as cytokeratin-7 (CK7) and thyroid
transcription factor-1 (TTF1) which are diagnostic
markers of the tumor [5, 6].
Lung adenocarcinomas belong to the first types of tu-
mors where the importance of driver mutations has been
discovered. So far treatment options are guided by the
KRAS and the epidermal growth factor receptor (EGFR)
status as the majority of mutations can be detected on
KRAS exon 2 and EGFR exon 19, 21 [7–10]. EGFR signal-
ing activates downstream pathways such as Akt/mTOR
and MEK/Erk which then promote cell proliferation [11].
Because of the high representation of adenocarcinoma
and its relative great number of targetable mutations com-
pared to other cancer types it is one of the best examined
cancer [3]. For in vitro studies cell lines are available, but
for in vivo experiments the opportunities are limited.
Lung cancer is inducible in mouse with Jaaksiegte sheep
retrovirus, but only in the immunocompromised strains
[12]. Benzopyrene and 4-(methylnitrosamino)-1-(3-pyri-
dyl)-1-butanone induced lung carcinogenesis is a known
and described way to create lung tumors, but only in few
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strains [13]. A Cre-recombinase mediated model also ex-
ists [14]. Here we present another easy way to develop
lung adenocarcinoma in FVB/N mouse strain.
Diethylnitrosamine (DEN) is a well-known and widely
used chemical compound to cause cancer in vivo [15].
The mechanism of action of DEN involves it’s adduct for-
mation potential. After it’s bioactivation by CYP450 en-
zymes it transforms to be a strong alkylating agent that
will form adducts in the DNA, which results in a direct
carcinogen effect [16]. We injected FVB/N mice with one
single dose of DEN. This lung carcinogen effect of DEN
was described earlier in A/J mouse strain [17]. A/J strain
is susceptible to lung cancer and after DEN exposure they
developed lung adenocarcinomas which were positive for
KRAS mutation in the 80% of the cases [17].
FVB/N mouse strain has also high susceptibility for
lung cancer [18]. An aging study with FVB/N strain pub-
lished in the literature indicated that lung and liver can-
cer were the two most represented tumor types
developed. At age 14 months 14% of the population had
lung cancers, but there were no liver tumors. The
former increased to 38% in the 24 months old popula-
tion but only 6% had liver cancer. The population con-
tained both males and females [18].
Our primary aim was to assess the lung cancer initi-
ation potency of DEN in FVB/N strain and also deter-
mine the KRAS and EGFR status of the tumors which
could later serve as a new model for NSCLC research.
We wanted to compare the characteristics of DEN in-
duced and spontaneously developed lung tumors by
their markers and molecular status. We also aimed to
determine the main signaling pathways driving tumor
proliferation together with the status of the cell cycle.
Methods
Animals and treatments
All animal experiments were conducted according to the
ethical standards of the Animal Health Care and Control
Institute Csongrád County, Hungary. The protocol was
approved by the Committee of the Animal Health Care
and Control Institute Csongrád County, Hungary (per-
mit No. XVI/03047–2/2008).
FVB/N mice were purchased from Charles Rivers. A
total of 40 animals (20 male and 20 female) were utilized
for carcinogenesis experiments. A single dose (15 μg/g
body weight) of DEN (N0258, Sigma-Aldrich, St. Louis,
Missouri, US) was injected intraperitoneally at the age of
15 days. DEN concentration was chosen to be low
enough to minimalize mutation occurrence and high
enough for tumor formation within a year. A total of 14
mice served as age-matched untreated controls. Animals
were terminated one year after DEN exposure by cer-
vical dislocation in ether anesthesia. The body, lung and
liver weight of mice were measured, and the number of
macroscopically detectable tumors was recorded. Sam-
ples were fixed in 10% buffered formaldehyde and em-
bedded in paraffin for histological analysis.
For generating subcutaneously maintained lung carcin-
oma, lung tumors were removed, cut into small pieces,
washed in PBS and transplanted subcutaneously in an-
other FVB/N mouse. The tumor was passaged when ne-
cessary. Samples were stored at − 70 °C. DNA was
isolated from the primary tumor and tumor from the
14th passage.
Immunohistochemistry
Formalin-fixed paraffin-embedded (FFPE) sections were
dewaxed in xylene and ethanol then washed in distilled
H2O. Antigen retrieval was carried out with citrate buf-
fer (10 mM citric acid, 0.05% Tween 20, pH = 6.0) in a
pressure cooker for 20 min. Slides were washed three
times in phosphate buffered saline + 0.05% Tween 20
(PBST). Endogenous peroxidase block was applied for
10 min with 3% H2O2. After another washing procedure
5 w/v% bovine serum albumin (BSA)/PBS was used to
block non-specific antibody binding sites. Primary anti-
bodies were dissolved in 1 w/v% BSA/phosphate buff-
ered saline (PBS) and applied for overnight at 4 °C.
Primary antibodies were rabbit monoclonal anti-TTF1
(ab76013, Abcam, Cambridge, UK, dilution: 1:50) and
rabbit polyclonal anti-CK7 (HPA007272, Atlas anti-
bodies, Stockholm, Sweden, dilution: 1:100). The next
day PBST wash was applied for 5 × 5 minutes. Secondary
antibody was horse-radish peroxidase (HRP) conjugated
anti-rabbit antibody (P0448, Dako, Glostrup, Denmark)
applied for 1 h. After washing procedure signals were vi-
sualized with 3,3-diaminobenzidine tetrahydrochloride
(DAB) substrate chromogen solution (Novolink Polymer
Detection System, RE7150-K, Leica Biosystems, Wetzlar,
Germany). Nuclei were stained by hematoxillin. The
slides were scanned, and viewed with Pannoramic
Viewer (3D Histech Ltd., Budapest, Hungary).
Sanger sequencing
DNA isolation from frozen tissue and from FFPE sections
Frozen tumorous tissue was homogenized in liquid ni-
trogen and suspended with 400 μl lysis buffer (0.2 M
NaCl, 0.02 M EDTA, 0.04 M Tris and 0.5% SDS) supple-
mented with 20 μl Proteinase K (10 mg/ml, Roche,
Basel, Switzerland) and 2 μl β-mercaptoethanol.
On FFPE sections, tumorous area was marked under
light microscope. Next, slides were dewaxed, and then
rinsed in acetone and alcohol. After drying, the marked
tumorous areas were removed by a scalpel and incu-
bated in Tris-EDTA (10 mM Tris, 1 mM EDTA, pH =
7.4) buffer containing 2 mg/ml Proteinase K at 55 °C
overnight with 300 rpm shaking to remove proteins.
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The enzyme was heat-inactivated at 95 °C for 10 min
followed by 15 min incubation on ice. Lysates were centri-
fuged at 13000 rpm for 15 min. The supernatants were
kept and 50 μl, 5 M NaCl was added and incubated for
another 15 min on ice. After centrifugation with
13,000 rpm for 10 min, 1 ml of ice-cold ethanol was added
to each supernatant to precipitate DNA. The samples
were centrifuged with 13,000 rpm for 10 min and the pel-
lets were dried out with Savant AES 1000 SpeedVac sys-
tem (Thermo Fischer Scientific, Waltham, MA). Pellets
were dissolved in 50 μl TE buffer and DNA concentra-
tions were measured with NanoDrop ND-1000 spectro-
photometer (Thermo Fischer Scientific, Waltham, MA).
Polymerase chain reaction (PCR)
Primers designed for mouse EGFR exon 19, 21 and
KRAS exon 2 are shown in Table 1.
Reactions were performed in a total volume of 20 μl.
ImmoMix Red 2× (BIO-25002, Bioline, London, UK)
reaction-mix was used for the PCR. Twenty pmol of for-
ward and reverse primer (Integrated DNA Technologies,
Coralville, IA), MgCl2 (BIO-37026, Bioline, London, UK)
and 50 ng DNA was added to each reaction. Thermal
cycle parameters were as follows: 95 °C initial denatur-
ation for 10 min followed by 40 cycles of denaturation at
95 °C for 40 s, annealing at appropriate temperature for
40 s (59 °C for KRAS exon 2, 56 °C for EGFR exon 19,
57 °C for EGFR exon 21 primers), elongation at 72 °C
for 40 s. PCR was carried out using Veriti 96 Well Ther-
mal Cycler (Thermo Fischer Scientific, Waltham, MA).
PCR products were checked on a 2% agarose gel by
electrophoresis.
Cycle sequencing and electrophoresis
For PCR product clean-up, ExoSap (Cat. no.: 78201,
Affymetrix, Cleveland, OH) was applied following the
instructions of the manufacturer. Cycle sequencing re-
actions were conducted using BigDye Terminator
v3.1 Cycle Sequencing Kit (Cat. no.: 4337454, Thermo
Fischer Scientific, Waltham, MA) as specified in the
user guide. The subsequent cleaning step was per-
formed with Nucleo-SEQ kit (Cat. no.: 740523,
Macherey-Nagel, Düren, Germany) as described in the
user manual. The samples were eluted in 20 μl
formamide and denatured at 95 °C for 1 min. Capil-
lary electrophoresis was carried out on a 3500 Series
Genetic Analyzer (Thermo Fischer Scientific, Wal-
tham, MA). Sequences were analyzed using BioEdit
Sequence Alignment Editor (Ibis Biosciences, Carls-
bad, CA).
Western blot
Frozen tissues were homogenized and suspended with
lysis buffer (containing: 20 mM Tris pH = 7.5, 150 mM
NaCl, 2 mM EDTA, 0.05% Triton X-100, 0.5% Protease
Inhibitor Cocktail (P8340, Sigma-Aldrich, St. Louis,
MO), 2 mM Na3VO4 and 10 mM NaF). Protein concen-
trations were measured by Bradford method. For normal
lung and primary tumors, lysates of 5 different speci-
mens were pooled to generate one sample, and 3 differ-
ent samples were prepared. Pooled primary tumor
samples were individually analyzed checking for diversity
(Additional file 1: Fig. S1). The selected proteins dis-
played quite homogenous distribution proving the ap-
plicability of pooled samples later on (Additional file 1:
Fig. S1). For subcutaneous tumors, 1 tumor sample was
run in each experiment. Thirty μg of total proteins were
mixed with loading buffer containing β-
mercaptoethanol and denatured at 99 °C for 5 min.
Denatured samples were loaded onto a 10% SDS-
polyacrylamide gel and separated for 40 min at 200 V.
Proteins were transferred to a PVDF membrane with
overnight blotting at 4 °C at constant 75 mA. Blotting
efficiency was checked by Ponceau staining. Blocking
procedure was carried out with 5% non-fat dry milk
dissolved in Tris-buffered saline (TBS) applied for 1 h.
Next, membranes were incubated overnight with pri-
mary antibodies. After washing with TBST (TBS +
0.05% Tween 20), appropriate secondary antibody dis-
solved in 1% non-fat dry milk (TBS) was applied for 1 h
at room temperature. After washing, immunoreactions
were visualized using SuperSignal West Pico Chemilu-
minescent Substrate kit (Cat. no.: 34078, Thermo Fi-
scher Scientific, Waltham, MA). Bands were detected
with Kodak Image Station 4000MM (Kodak, Rochester,
NY). Western blots were run in 3 independent experi-
ments. Antibodies with their appropriate dilutions used
for Western blots are shown in Table 2.
Results
Activity of DEN to induce lung cancer
We found DEN to be a potent lung carcinogen in the
FVB/N mouse strain. Out of 39 mice, 28 developed
macroscopic lung tumors. Six of them had multiple neo-
plasia (Table 3). The tumor prevalence between the gen-
ders showed only minor differences and no differences in
lung mass was observed (Table 3). Histologically, tumors
appeared to be papillary carcinomas, their morphology
Table 1 Primer sequences
Gene Primer sequence
EGFR exon 19 forward 5’-CTGGATCCCAGAAGGTGAGA-3’
EGFR exon 19 reverse 5’-GGAAGCAAGATTGACCTTATGAA-3’
EGFR exon 21 forward 5’-TTGGCAGCCAGGAATGTACT-3’
EGFR exon 21 reverse 5’-GGCTGTCAGGAAAATGCTTC-3’
KRAS exon 2 forward 5’-TGTAAGGCCTGCTGAAAATG-3’
KRAS exon 2 reverse 5’-GCACGCAGACTGTAGAGCAG-3’
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was very similar to that observed in human disease. Most
tumors were moderately or well-differentiated, a few
showed poorly differentiated appearance. Multiple neopla-
sias often had mixed phenotype.
Out of 14 untreated control only two mice developed
spontaneous lung adenocarcinoma (Table 4). Only males
were observed in the control group because there was
no significant difference in the lung tumor development
between the males and females in the literature [18].
The two tumors appeared to be poorly differentiated
papillary carcinomas; however the low number prevents
its comparison to DEN-induced tumors.
Histochemical markers of lung adenocarcinoma
With immunostaining all the 28 tumorous tissues
showed high level of CK7 and TTF1 expression which
confirmed the lung adenocarcinoma diagnosis (Fig. 1).
The spontaneous lung tumors also showed CK7 and
TTF1 positivity.
KRAS and EGFR sequencing
KRAS and EGFR mutation hot spots were analyzed in
all tumorous samples including spontaneous tumors. No
mutations were found in KRAS exon 2 and in EGFR
exons 19 and 21 (Fig. 2).
Alterations in signaling pathways
Akt/mTOR, ERK pathways and G1/S restriction point
were analyzed by Western blot technique. We compared
normal FVB/N lung tissue with the DEN induced pri-
mary adenocarcinoma and with the subcutaneously
maintained lung tumor. The amount of Akt phosphory-
lated at Thr308 and Ser473 significantly decreased in the
subcutaneously maintained sample, and p-Akt Thr308 in
the DEN induced primary tumor showed similar ten-
dency compared to the normal lung tissue, whereas
Ser473 remained unchanged in the primary tumor. On
the other hand p-S6 increased ~ 5-fold in both tumor
samples. While p-Erk1/2 in the primary tumor did not
differ from the control, it was greatly increased (20% and
80% respectively) in the subcutaneously maintained
tumor compared to the normal tissue. The phosphoryl-
ation of GSK3β decreased in the subcutaneous adeno-
carcinoma, while it remained unchanged in the primary
tumor (Fig. 3).
Regarding cell cycle regulation, the level of CDK4 re-
sponsible for retinoblastoma phosphorylation in G1-S
transition, increased with ~ 4-fold in both tumor samples.
Phospho-Rb S780 increased significantly in the primary
tumor, but interestingly decreased in the subcutaneous
tumor. The S-phase marker PCNA showed a remarkable
~ 18-fold elevation in the primary tumor and ~ 25-fold in
the subcutaneous tumor compared to the normal tissue
indicating their increased proliferation. (Fig. 4).
Discussion
DEN is a commonly used agent to induce liver cancer
[15, 19]. In addition, some literature data indicates that
chemical carcinogens, such as DEN, can be a potent
lung carcinogen in strains where the frequency of the
lung tumors was already higher than any other cancer
[13, 14, 17]. In the literature DEN was used in a concen-
tration of 50 mg/kg to induce lung tumor and only
Table 4 Tumor prevalence in control, untreated FVB/N mice
Total No. Animals with
macroscopic
lung tumors
Average lung mass Average lung
mass/ body
mass (%)
14 2 0.15 g 0.5
Table 3 Tumor prevalence in FVB/N mice induced by DEN
Gender Total No. Animals with
macroscopic
lung tumors
Average
lung mass
Average lung
mass/ body mass (%)
Male 19 15 0.24 g 0.78
Female 20 13 0.23 g 0.78
Table 2 Antibodies and their specifications
Primary antibody Manufacturer Catalog number Source Dilution
Akt Cell Signaling Technology, Danvers, MA #4691 rabbit 1:1000
p-Akt (Thr308) Cell Signaling Technology #2965 rabbit 1:1000
p-Akt (Ser473) Cell Signaling Technology #4058 rabbit 1:1000
p-Erk 1/2 Cell Signaling Technology #4370 rabbit 1:1000
p-GSK3 α/β Cell Signaling Technology #9331 rabbit 1:500
p-S6 Cell Signaling Technology #2211 rabbit 1:1000
CDK4 Neomarkers, Fremont, California, US #MS-616 mouse 1:250
PCNA Atlas antibodies, Stockholm, Sweden HPA030522 rabbit 1:1000
p-Rb S780 Cell Signaling Technology #9307 rabbit 1:250
β-actin Sigma-Aldrich, St. Louis, MO A2228 mouse 1:5000
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KRAS was analyzed, which was found to be 80% mu-
tated. We applied a single dose of 15 μg/g intraperitone-
ally, hypothetically low enough to minimize mutation
occurrence and ideally avoid mutations in KRAS and
EGFR genes. In our cases neither primary nor subcuta-
neously maintained tumors harbored mutations in EGFR
exon 19, 21 or KRAS exon 2. These data may indicate a
dose dependent mutation forming effect, but a more
probable hypothesis is that the A/J mouse strain is more
susceptible to lung cancer with mutant KRAS, simply
because of it has different genetic background compared
to that of FVB/N. In human adenocarcinomas the fre-
quency of EGFR mutations is estimated between 15 and
45%, whereas KRAS mutation was detected in 20% of
the cases depending on the geographical region [20].
However, our model could represent the portion of hu-
man adenocarcinomas negative for KRAS and EGFR
mutations.
Fig. 2 Mutation analysis by Sanger sequencing. (a) KRAS sequence, (b) EGFR exon 19 sequence, (c) EGFR exon 21 sequence; Regions of potential
mutations are marked in the sequences
Fig. 1 Histological analysis of primary, subcutaneous and spontaneous lung adenocarcinoma. (a-c) Primary tumor; (d-f) Subcutaneous tumor; (g-i)
Spontaneous tumor, (a,d,g) Hematoxylin and eosin staining. Immunostaining of cytokeratin-7 (b,e,h) and TTF1 (c,f,i). Primary and subcutaneous tumors
are from different animals. Scale bar = 50 μm
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FVB/N mice is a well-known and described mouse strain,
which is more susceptible to develop spontaneous lung can-
cer than any other tumor and the ratio of liver tumors are
lower than in other strains [18]. This susceptibility can ex-
plain why DEN induced tumors predominantly in the lung,
and very few in the liver until the 1st year endpoint. DEN
might speed up the already existing susceptibility for lung
cancer formation which theory is in harmony with other lit-
eratures [14]. Regarding morphology, tumors in our model
appeared to be papillary carcinomas, all TTF-1 and
cytokeratin-7 positive analogous to human lung cancers.
The increased p-S6 indicates a more active mTOR sig-
naling which leads to cell proliferation [21]. Interestingly
the amount of both p-Akt is decreased in the subcutane-
ously maintained tumor and a reduction can also be
seen in the level of p-Akt Ser473 in the primary tumor,
as well. Phosphorylation of Erk1/2 increased in the sub-
cutaneous tumor which can be one of the mechanism
that results in active mTOR pathway [22]. The decreased
amount of p-GSK3 correlates well with the low level of
p-Akt in all the samples.
The proliferation stimuli results in a constantly work-
ing cell cycle which can be seen in the two tumorous
samples. CDK4 and the S phase marker PCNA are
greatly increased in both tumors compared to the nor-
mal lung sample [23, 24]. Increased p-Rb S780 in the
primary tumor also confirms this, but interestingly it de-
creased in the subcutaneous tumor. This could be ex-
plained by the hyperphosphorylation of Rb which can
lead to its degradation [25]. It is also possible that Rb
protein was lost due to deleterious mutation [26].
These results prove that the FVB/N mouse strain can
be used for lung cancer experiments, because chemical
carcinogens speed-up its already accelerated lung
tumorigenesis resulting adenocarcinomas. In addition,
our model is unique as it can better represent human
Fig. 4 Western blot analysis of the main cell cycle proteins. The data are the mean ± SD of 3 experiments, *P < 0.05; **P < 0.01 and ***P < 0.001.
Blots are separate images
Fig. 3 Western blot analysis of the main signaling pathways. The data are the mean ± SD of 3 experiments, *P < 0.05; **P < 0.01 and ***P < 0.001.
Blots are separate images
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lung adenocarcinoma cases with no common KRAS
and EGFR mutations. Thus we believe that this well-
characterized model with unraveled signaling pathways
has a value in both academic and practical use.
Conclusions
We found diethylnitrosamine as a potent chemical sub-
stance to induce lung adenocarcinoma in FVB/N mouse
strain. The tumor was positive for CK7 and TTF1. We
found no mutations in KRAS exon 2 and EGFR exon 19
and 21. The proliferation of the tumors is driven by the
MAPK and mTOR pathways ending up with the stimu-
lation of cell cycle at the G1/S restriction point. The
model could be a useful tool in lung cancer research tar-
geting KRAS and EGFR negative tumors.
Additional file
Additional file 1: Figure S1. Western blot analysis of pooled tumor
samples. (A) Image of Western blot run loaded with individual primary
tumor samples. (B-C) Quantification of various protein amounts. (D)
Average of protein levels measured in individual tumors (data are
expressed as mean ± SD). (JPEG 522 kb)
Abbreviations
BSA: bovine serum albumin; CDK: cyclin-dependent kinase; CK7: cytokeratin-
7; DAB: 3,3-diaminobenzidine; DEN: diethylnitrosamine; EGFR: epidermal
growth factor receptor; FFPE: Formalin-fixed paraffin-embedded; HRP: horse-
radish peroxidase; KRAS: Kirsten rat sarcoma; mTOR: mammalian target of
rapamycin; NSCLC: non-small cell lung cancer; PBS: phosphate-buffered
saline; PCNA: Proliferating cell nuclear antigen; PCR: polymerase chain
reaction; Rb: retinoblastoma; SCLC: small cell lung cancer; TBS: tris-buffered
saline; TTF1: thyroid transcription factor-1
Acknowledgements
The authors would like to thank András Sztodola for his valuable help in the
animal nursing.
Funding
This work was supported by Hungarian Research Fund (OTKA) (No. 100904
to Ilona Kovalszky; and No. 105763 to Kornélia Baghy). The funding body had
no role in the design of the study and collection, analysis, and interpretation
of data and in writing the manuscript.
Availability of data and materials
The datasets used and/or analyzed during the current study available from
the corresponding author on reasonable request.
Authors’ contributions
Zsolt Mervai conducted most of the experiments and drafted the
manuscript. Krisztina Egedi performed the Sanger sequencing. Ilona
Kovalszky and Kornélia Baghy designed the study and drafted the
manuscript. All authors read and approved the final manuscript.
Competing interest
The authors declare that they have no competing interests.
Ethics approval
All animal experiments were conducted according to the ethical standards of
the Animal Health Care and Control Institute Csongrád County, Hungary. The
protocol was approved by the Committee of the Animal Health Care and
Control Institute Csongrád County, Hungary (permit No. XVI/03047–2/2008).
Consent for publication
Not applicable.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Received: 3 November 2016 Accepted: 29 January 2018
References
1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber
H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe:
estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin.
2014;64(1):9–29.
3. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung
cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin
Proc. 2008;83(5):584–94.
4. Subramanian J, Govindan R. Lung cancer in never smokers: a review.
Journal of clinical oncology : official journal of the American Society of
Clinical Oncology. 2007;25(5):561–70.
5. Su YC, Hsu YC, Chai CY. Role of TTF-1, CK20, and CK7
immunohistochemistry for diagnosis of primary and secondary lung
adenocarcinoma. Kaohsiung J Med Sci. 2006;22(1):14–9.
6. Cai YC, Banner B, Glickman J, Odze RD. Cytokeratin 7 and 20 and thyroid
transcription factor 1 can help distinguish pulmonary from gastrointestinal
carcinoid and pancreatic endocrine tumors. Hum Pathol. 2001;32(10):1087–93.
7. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan
BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. Activating mutations
in the epidermal growth factor receptor underlying responsiveness of non-
small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.
8. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P,
Kaye FJ, Lindeman N, Boggon TJ, et al. EGFR mutations in lung cancer:
correlation with clinical response to gefitinib therapy. Science. 2004;
304(5676):1497–500.
9. Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, Nafa K,
Riedel ER, Hsu M, Pao W, et al. Frequency and distinctive spectrum of
KRAS mutations in never smokers with lung adenocarcinoma. Clinical
cancer research : an official journal of the American Association for
Cancer Research. 2008;14(18):5731–4.
10. Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH. EGFR and KRAS
mutations in patients with adenocarcinoma of the lung. Korean J Intern
Med. 2009;24(1):48–54.
11. Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy
and beyond. Mod Pathol. 2008;21(Suppl 2):S16–22.
12. Wootton SK, Halbert CL, Miller AD. Sheep retrovirus structural protein
induces lung tumours. Nature. 2005;434(7035):904–7.
13. Hecht SS, Isaacs S, Trushin N. Lung tumor induction in a/J mice by the
tobacco smoke carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
and benzo[a]pyrene: a potentially useful model for evaluation of
chemopreventive agents. Carcinogenesis. 1994;15(12):2721–5.
14. Meuwissen R, Berns A. Mouse models for human lung cancer. Genes Dev.
2005;19(6):643–64.
15. Kushida M, Kamendulis LM, Peat TJ, Klaunig JE. Dose-related induction of
hepatic preneoplastic lesions by diethylnitrosamine in C57BL/6 mice.
Toxicol Pathol. 2011;39(5):776–86.
16. Verna L, Whysner J, Williams GM. N-nitrosodiethylamine mechanistic data
and risk assessment: bioactivation, DNA-adduct formation, mutagenicity,
and tumor initiation. Pharmacol Ther. 1996;71(1–2):57–81.
17. You M, Wang Y, Lineen AM, Gunning WT, Stoner GD, Anderson MW.
Mutagenesis of the K-ras protooncogene in mouse lung tumors
induced by N-ethyl-N-nitrosourea or N-nitrosodiethylamine.
Carcinogenesis. 1992;13(9):1583–6.
18. Mahler JF, Stokes W, Mann PC, Takaoka M, Maronpot RR. Spontaneous
lesions in aging FVB/N mice. Toxicol Pathol. 1996;24(6):710–6.
19. Goldfarb S, Pugh TD, Koen H, He YZ. Preneoplastic and neoplastic
progression during hepatocarcinogenesis in mice injected with
diethylnitrosamine in infancy. Environ Health Perspect. 1983;50:149–61.
20. Arrieta O, Cardona AF, Martin C, Mas-Lopez L, Corrales-Rodriguez L, Bramuglia G,
Castillo-Fernandez O, Meyerson M, Amieva-Rivera E, Campos-Parra AD, et al.
Updated frequency of EGFR and KRAS mutations in NonSmall-cell lung
cancer in Latin America the Latin-American consortium for the investigation of
lung cancer (CLICaP). J Thorac Oncol. 2015;10(5):838–43.
Mervai et al. BMC Cancer  (2018) 18:157 Page 7 of 8
21. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR
controls cell cycle progression through its cell growth effectors S6K1
and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol.
2004;24(1):200–16.
22. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-
talk and compensation. Trends Biochem Sci. 2011;36(6):320–8.
23. Foster DA, Yellen P, Xu L, Saqcena M. Regulation of G1 cell cycle
progression: distinguishing the restriction point from a nutrient-sensing cell
growth checkpoint(s). Genes Cancer. 2010;1(11):1124–31.
24. Landberg G, Roos G. Antibodies to proliferating cell nuclear antigen as
S-phase probes in flow cytometric cell cycle analysis. Cancer Res. 1991;
51(17):4570–4.
25. Ma D, Zhou P, Harbour JW. Distinct mechanisms for regulating the tumor
suppressor and antiapoptotic functions of Rb. J Biol Chem. 2003;278(21):
19358–66.
26. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006;
25(38):5220–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Mervai et al. BMC Cancer  (2018) 18:157 Page 8 of 8
